Table 1.
Organisms | Threat Level | Estimated Cases in Hospitalized Patients (2017) | Estimated Deaths (2017) | Estimated Attributable Healthcare Costs (2017) US |
---|---|---|---|---|
Carbapenem-resistant Acinetobacter | Urgent | 8,500 | 700 | $281M |
Clostridioides difficile | Urgent | 223,900 | 12,800 | $1B |
Carbapenem-Resistant Enterobacteriaceae | Urgent | 13,100 | 1,100 | $130M |
Drug-Resistant Neisseria gonorrhoeae | Urgent | 550,000 | 1.14M | $133.4M |
Vancomycin-Resistant Enterococci (VRE) | Serious | 54,500 | 5,400 | $539M |
Multidrug-Resistant Pseudomonas aeruginosa | Serious | 32,600 | 2,700 | $767M |
Methicillin-Resistant Staphylococcus aureus | Serious | 323,700 | 10,600 | $1.7B |
Extended-Spectrum Beta-Lactamase (ESBL) Producing Enterobacteriaceae | Serious | 197,400 | 9,100 | $1.2B |
Drug-Resistant Tuberculosis (Tb) | Serious | 847 | 62 | $164,000 Per MDR case $526,000 Per XDR case |
Note: Data from Centers for Disease Control and Prevention.19